James Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James Campbell has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Alonso de la Vega
The Francis Crick Institute 1 London
31 shared publications - Andrea de Castro
The Francis Crick Institute 1 London
31 shared publications - Anna Mikolajczak
Experimental Histopathology Science Technology Platform, The Francis Crick Institute 5 , London
31 shared publications - Christopher Moore
The Francis Crick Institute 1 London
31 shared publications - Claire E. Pillsbury
The Francis Crick Institute 1 London
31 shared publications - Julian Downward
Oncogene Biology Laboratory, The Francis Crick Institute, London, UK
31 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Spectral flow cytometry staining panel for analysis of Emv2-specific T cells
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Spectral flow cytometry staining panel for analysis of Emv2-specific T cells
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Adaptive immunity is required for durable responses
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Adaptive immunity is required for durable responses
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Table S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Table S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Spectral flow cytometry gating strategy
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Spectral flow cytometry gating strategy
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Predicted MHC-I binding affinities for eBFP peptides
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Predicted MHC-I binding affinities for eBFP peptides
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Generation of reporter-transduced KPAR1.3 cell lines
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Generation of reporter-transduced KPAR1.3 cell lines
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Combination strategies to enhance treatment responses
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Combination strategies to enhance treatment responses
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
RNAseq analysis of proliferation-associated tumor cell signatures
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
RNAseq analysis of proliferation-associated tumor cell signatures
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Triple combination increases the generation of complete responders
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
Triple combination increases the generation of complete responders
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
TME phenotyping via spectral flow cytometry
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
TME phenotyping via spectral flow cytometry